Breaking News

Immutep, Merck KGaA and Pfizer Enter Clinical Trial Collaboration

To evaluate new combination study of first-in-class LAG-3 candidate, eftilagimod alpha, and avelumab to treat urothelial cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has signed a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005.   INSIGHT-005 will be an open-label study evaluating the safety and efficacy of Immutep’s lead product candidate, efti, in combination with avelumab (BAVENCIO) in up to 30 patie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters